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wIn the context of the current healthcare reform
debate, the ongoing, rapid growth of cardiac imag-
ing has triggered efforts to improve appropriate use
and contain costs of diagnostic testing. As part of
this, the process of test evaluation and validation
has shifted from a focus on diagnostic accuracy to
See pages 481 and 496
the use of risk-based criteria. Optimally, evidence of
improved risk stratification directing subsequent
treatment decisions will justify and guide appropri-
ate use of an imaging test, in comparison with other
diagnostic strategies. Such comparative effective-
ness data is still sparse for cardiovascular imaging,
and current clinical guidelines are often based on
expert consensus rather than evidence alone (1).
Coronary imaging is a representative example. In
the late 1950s, the introduction of coronary angiog-
raphy completely transformed the treatment of
patients with coronary artery disease (CAD). Even
though large outcome trials satisfying current stan-
dards were lacking, coronary angiography was rap-
idly integrated into clinical care, and for a long
period, was considered the “Holy Grail” in cardiol-
ogy. The common strategy of imaging was the
identification of focal, hemodynamically significant
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oronary revascularization. In recent years, there has
een a shift from the identification of hemodynamic
tenosis alone to image-based identification of pa-
ient risk. Clinical trials using such data as the basis
or subsequent treatment decisions have allowed
etter definition of the benefit of revascularization
ersus optimal medical management (2).
Secondary analysis of data from imaging studies
erformed for the identification of hemodynamically
ignificant coronary stenosis has demonstrated that
hese tests yield additional prognostic value for the
rediction of future cardiovascular events. For func-
ional modalities (echocardiography, cardiac magnetic
esonance, perfusion imaging), left ventricular ejection
raction, extent of ischemia, and scar are strongly
ssociated with adverse outcomes. For anatomic mo-
alities, the extent and distribution of atherosclerotic
isease burden (combining luminal stenosis and ath-
rosclerotic plaque burden, plaque morphology, and
omposition) have prognostic implications.
This concept has been well validated with coronary
omputed tomography angiography (CTA), with
ultiple studies demonstrating that the extent and
everity of coronary atherosclerosis has prognostic
alue (3–6). A recent meta-analysis summarized re-
ults from 18 studies including 9,592 patients with
uspected or known CAD (7). During a median
ollow-up of 20 months, 449 major adverse cardiovas-
ular events (MACE) occurred, including 180 deaths,
6 myocardial infarctions (MI), and 213 revascular-
zations, consistent with an event rate of 4.7% for
ACE and 2.4% for death and MI. The pooled
nnualized event rate for obstructive (any vessel with
50% luminal stenosis) versus normal coronary CTA
as 8.8% versus 0.17% per year for all MACE (p 
.05) and 3.2% versus 0.15% for death or MI (p 
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4930.05). Strata of “absent CAD,” “nonobstructive
CAD” (worst stenosis 50%), or “obstructive CAD”
demonstrated incremental increases in the risk of
future MACE (0.17%, 1.41%, and 8.84%, respec-
tively). The data demonstrated several important is-
sues. First, adverse cardiovascular events among pa-
tients with normal findings on coronary CTA were
rare, similar to the background event rate among
healthy low-risk individuals (1%). Interestingly, this
vent rate was lower than that previously reported
rom other imaging modalities including stress echo-
ardiography and myocardial perfusion imaging (8–10).
onetheless, coronary CTA satisfied the basic te-
ets of successful risk stratification (i.e., identifica-
ion of a low-risk patient subset, defining gradations
f risk on the basis of test abnormality and concen-
rating risk in patients with abnormal tests) (11).
econd, the presence of “significant” stenosis
50% luminal diameter stenosis) is associated with
ignificantly higher risk than nonobstructive athero-
clerotic changes, supporting observations that have
n the past been made with invasive coronary
ngiography. Lastly, although adverse events were
ignificantly more common among patients with
bnormal coronary CTA findings, the majority of
atients with disease did not have adverse out-
omes. In other words, even a positive computed
omography (CT) scan was not strongly predictive
f future MACE.
The paper by Schlett et al. (12) in this issue of
JACC provides further data concerning the prog-
ostic value of coronary CTA. It focuses on a
pecific patient group; patients who had presented
o the emergency department with acute chest pain
ut negative initial troponin and electrocardiogram.
t is an extension of the ROMICAT (Rule Out
yocardial Infarction/Ischemia Using Computer
ssisted Tomography) trial in which the use of
oronary CTA for the initial management of such
atients had been investigated (13). Schlett et al.
12) now report the 2-year follow-up of 333 pa-
ients. The presence of plaque, luminal stenosis
50%), and left ventricular regional wall motion
bnormalities (RWMA) were assessed. The pri-
ary endpoint was a composite of cardiac death,
onfatal MI, and coronary revascularization. At the
nd of the follow-up period, 25 patients had 35
ACE (0 cardiac deaths, 12 MI, and 23 revascu-
arizations), for an event rate of 6.8% for MACE
nd 3.3% for death or MI. The cumulative proba-
ility of 2-year MACE increased across CT strata
or CAD (no CAD 0.0%, nonobstructive CAD
.6%, obstructive CAD 30.3%; log-rank p 0.0001) and across combined CT strata for CAD
and RWMA, thus achieving significant risk strati-
fication. The C statistic for predicting MACE was
0.61 for clinical Thrombolysis In Myocardial In-
farction risk score, improved to 0.84 by adding CT
CAD data, and further improved to 0.91 by adding
RWMA (both p  0.0001).
Several important issues merit mention. First, the
authors did not differentiate between revasculariza-
tion performed early versus late after coronary CTA
(before vs. after 60 to 90 days post-testing). The
latter is an accepted endpoint related to progression
of CAD, whereas the former is more critical. It is
related to the results of initial presentation and
workup and thus can be a very different phenome-
non. Previous studies that addressed the use of
coronary CTA for diagnostic purposes typically
excluded early revascularizations (6,14,15) to avoid
a “self-fulfilling prophecy”: a positive CT triggers
revascularization, which in turn would be used as
evidence that CT has prognostic relevance. How-
ever, in the ROMICAT trial, the results of CTA
were not communicated to the treating physicians
and hence—different than other prognostic trials of
coronary CTA—CT interpretation did not influ-
ence decisions on early revascularization. This mit-
igates some of the problems of including early
revascularizations. As another relevant issue, the
study cohort had an overall hard event rate (cardiac
death and MI) of 1.9% per year and therefore
onstituted a relatively low-risk group (12 MI in
33 patients over 23 months). Hence, 333 patients
ere tested to identify 183 at low risk (no obstruc-
ive CAD) and 25 who went on to have events,
ost of which were revascularizations, a relatively
oor yield. Finally, it was unclear whether the
esults of coronary CTA in these patients could
ave resulted in a change in patient management
hat would have yielded improved patient out-
omes, an important criterion for imaging in a
alue- or benefit-centered healthcare setting.
Interestingly, this issue of iJACC contains an-
other article on the prognostic value of coronary
CTA (16), in patients with prior coronary bypass
surgery, a patient group at substantially higher risk.
Of note, similar prognostic data have also been
described in recent CT studies examining calcifica-
tion and plaque of the aorta (17–19). Potentially,
review of CT scans performed for a wide range of
appropriate clinical indications (e.g., chest CT for
pulmonary embolism, assessment of the aorta, pre-
operative planning) could provide such prognostic
data.
g
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494These results are in line with our understanding
of CAD (20). Atherosclerosis is a systemic, inflam-
matory process occurring in the entire arterial tree
with various patterns of distribution and rates of
progression. Individual “vulnerable” lesions undergo
clinically unpredictable, sudden changes (rupture,
erosion, thrombosis), which in some, but not all,
instances initiate clinical events, including myocar-
dial or cerebral ischemia/infarction and limb isch-
emia/necrosis. Current diagnostic modalities can-
not reliably identify specific markers of impending
acute events (plaque vulnerability) and therefore do
not allow precise prediction of individual events.
However, post-test risk is greater in patients with
clinical cardiovascular risk factors, biochemical risk
markers (inflammation), and higher atherosclerotic
disease burden. Because of the systemic nature of
atherosclerosis, it is plausible that evidence and
extent of atherosclerotic disease (stenosis and non-
obstructive plaque) in any vascular arterial bed
indicates higher risk of future cardiovascular events.
Although convincing and in line with our under-
standing of the underlying systemic atherosclerotic
disease process, these data are still incomplete (21).
Understanding the relationship between diagnostic
imaging and outcome is further complicated by the
indirect relationship between the former and the
latter. Imaging impacts subsequent patient outcomes
only through its influence on downstream physician
decision making. The relationship between imaging
and downstream testing and therapeutic interventions
is not well understood, and many studies of post-
imaging outcomes fail to control or risk-adjust for
post-imaging patient management. This is a particular
concern in the setting of data collection in randomized
clinical trials examining noninvasive testing.
Further, applying a risk estimate to individual patients
requires a multicomponent, validated score, a much-
needed tool missing from our current imaging armamen-
tarium. Finally, as is the case for most imaging prognostic
data, it is important to incorporate risk assessment of
patients treated both medically and with revasculariza-
tion, thus permitting estimates of relative benefit and
identification of optimal patient management.
In summary, with the shift to a value-based health-
care system, the value of a test for the evaluation of
patients with known or suspected CAD is increasingly
seen in the ability of the test to risk-stratify and direct
downstream management, leading to improved clini-
cal outcomes. Although data for individual modalities
are accumulating, the relative value of different mo-systematically compared. Such an assessment will also
need to weigh risks of the test, including potential
downstream consequences of false positive results,
contrast administration, and radiation exposure (22).
For example, when compared with conventional an-
giography (7 mSv), sestamibi myocardial perfusion
imaging (12 mSv), and recent low-dose coronary
CTA acquisition protocols (3 mSv) (23,24), the radi-
ation exposure in the article by Schlett et al. (12) is
relatively high (estimated dose 14.7  2.2 mSv).
What we truly need are large, prospective clinical
trials that connect diagnostic testing with clinical
endpoints. One of the central questions in study
design will be whether downstream treatment de-
cisions following the imaging test will be mandated.
Such trials are currently enrolling patients, some
mandating treatment options (25) and others not
(26). Over the next several years, these data will
define the relative role of invasive and noninvasive
modalities and their cost effectiveness (27).
We currently face a situation with tremendous
opportunities but also tremendous challenges and
responsibilities: On one hand, imaging tests have
matured—such as coronary CTA, which continues
to provide ever more accurate images at ever lower
radiation exposure. Just as importantly, analyses
such as the studies by Schlett et al. (12) and Chow
et al. (16) in this issue of iJACC demonstrate
prognostic value of this new test in specific patient
populations. As outlined earlier, ongoing larger
trials using CT and other imaging modalities will
provide even more information regarding prognos-
tic implications of noninvasive imaging. Hence, the
medical community is gaining new tools of substan-
tial potential value. The tremendous responsibility
of researchers and clinicians is to define and adhere
to appropriate uses that translate into true benefit
for patients and society, improving outcomes while
avoiding higher healthcare expenditures. We ur-
gently need large-scale trials so that clinical guide-
lines based on comparative effectiveness data, rather
than expert consensus alone, will direct individual
patients to the most appropriate diagnostic ap-
proach and further treatment. Tremendous oppor-
tunities are in our hands—it is up to us to use them
to the maximum benefit of the patients who entrust
us with their well-being.
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11
1
1
1
1
1
1
1
2
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 5 , 2 0 1 1
M A Y 2 0 1 1 : 4 9 2 – 5
Schoenhagen et al.
Editorial Viewpoint
495R E F E R E N C E S
1. Taylor AJ, Cerqueira M, Hodgson
JM, et al. ACCF/SCCT/ACR/
AHA/ASE/ASNC/NASCI/SCAI/
SCMR 2010 appropriate use criteria
for cardiac computed tomography: a
report of the American College of
Cardiology Foundation. J Am Coll
Cardiol 2010;56:1864–94.
2. Boden WE, O’Rourke RA, Teo KK, et
al. Optimal medical therapy with or
without PCI for stable coronary disease.
N Engl J Med 2007;356:1503–16.
3. Min JK, Shaw LJ, Devereux RB, et al.
Prognostic value of multidetector cor-
onary computed tomographic angiog-
raphy for prediction of all-cause mor-
tality. J Am Coll Cardiol 2007;50:
1161–70.
4. Carrigan TP, Nair D, Schoenhagen P,
et al. Prognostic utility of 64-slice
computed tomography in patients
with suspected but no documented
coronary artery disease. Eur Heart J
2009;30:362–71.
5. Sozzi FB, Civaia F, Rossi P, et al.
Long-term follow-up of patients with
first-time chest pain having 64-slice
computed tomography. Am J Cardiol
2011;107:516–21.
6. Hadamitzky M, Freissmuth B, Meyer
T, et al. Prognostic value of coronary
computed tomographic angiography
for prediction of cardiac events in
patients with suspected coronary ar-
tery disease. J Am Coll Cardiol Img
2009;2:404–11.
7. Hulten EA, Carbonaro S, Petrillo SP,
Mitchell JD, Villines TC. Prognostic
value of cardiac computed tomogra-
phy angiography: a systematic review
and meta-analysis. J Am Coll Cardiol
2011;57:1237–47.
8. Wilson PW, D’Agostino RB, Levy D,
Belanger AM, Silbershatz H, Kannel
WB. Prediction of coronary heart dis-
ease using risk factor categories. Cir-
culation 1998;97:1837–47.
9. Metz LD, Beattie M, Hom R, Redberg
RF, Grady D, Fleischmann KE. The
prognostic value of normal exercise
myocardial perfusion imaging and exer-
cise echocardiography: a meta-analysis.
J Am Coll Cardiol. 2007;49:227–37.
10. Shaw LJ, Wilson PW, Hachamovitch
R, Hendel RC, Borges-Neto S, Ber-
man DS. Improved near-term coro-
nary artery disease risk classification
with gated stress myocardial perfusion
SPECT. J Am Coll Cardiol Img
2010;3:1139–48.1. Hachamovitch R, Di Carli MF. Con-
temporary reviews in cardiovascular
medicine: methods and limitations of
assessing new noninvasive tests: II.
outcomes-based validation and reli-
ability assessment of noninvasive test-
ing. Circulation 2008;117;2793–801.
2. Schlett CL, Banerji D, Siegel E, et
al. Prognostic value of CT angiog-
raphy for major adverse cardiac
events in patients with acute chest
pain from the emergency depart-
ment: 2-year outcomes of the
ROMICAT trial. J Am Coll Cardiol
Img 2011;4:481–91.
3. Hoffmann U, Bamberg F, Chae CU, et
al. Coronary computed tomography an-
giography for early triage of patients
with acute chest pain: the ROMICAT
(Rule Out Myocardial Infarction Using
Computer Assisted Tomography) trial.
J Am Coll Cardiol 2009;53:1642–50.
4. Hadamitzky M, Distler R, Meyer T,
et al. Prognostic value of coronary
computed tomographic angiography
in comparison with calcium scoring
and clinical risk scores. Circ Cardio-
vasc Imaging 2011;4:16–23.
5. Abidov A, Gallagher MJ, Chinnayan
KM, Mehta LS, Wegner JH, Raff
GL. Clinical effectiveness of coronary
computed tomographic angiography
in the triage of patients to cardiac
catheterization and revascularization
after inconclusive stress testing: results
of a 2-year prospective trial. J Nucl
Cardiol 2009;16:701–13.
6. Chow BJW, Ahmed O, Small G, et
al. Prognostic value of CT angiogra-
phy in coronary bypass patients. J Am
Coll Cardiol Img 2011;4:481–91.
7. Eisen A, Tenenbaum A, Koren-
Morag N, et al. Calcification of the
thoracic aorta as detected by spiral
computed tomography among stable
angina pectoris patients: association
with cardiovascular events and death.
Circulation 2008;118:1328–34.
8. Wong ND, Gransar H, Shaw L, et al.
Thoracic aortic calcium versus coro-
nary artery calcium for the prediction
of coronary heart disease and cardio-
vascular disease events. J Am Coll
Cardiol Img 2009;2:319–26.
9. Kurra V, Lieber ML, Sola S, et al.
Extent of thoracic aortic atheroma
burden and long-term mortality after
cardiothoracic surgery: a computed to-
mography study. J Am Coll Cardiol
Img 2010;3:1020–9.
0. Libby P, Ridker PM, Hansson GK;
Leducq Transatlantic Network onAtherothrombosis. Inflammation in
atherosclerosis: from pathophysiology
to practice. J Am Coll Cardiol 2009;
54:2129–38.
21. Hlatky MA, Greenland P, Arnett
DK, et al. Criteria for evaluation of
novel markers of cardiovascular risk: a
scientific statement from the Ameri-
can Heart Association. Circulation
2009;119:2408–16.
22. Halliburton SS, Schoenhagen P. Car-
diovascular imaging with computed
tomography: responsible steps to bal-
ancing diagnostic yield and radiation
exposure. J Am Coll Cardiol Img
2010;3:536–40.
23. Mark DB, Berman DS, Budoff MJ,
et al. ACCF/ACR/AHA/NASCI/
SAIP/SCAI/SCCT 2010 expert con-
sensus document on coronary com-
puted tomographic angiography: a
report of the American College of
Cardiology Foundation Task Force on
Expert Consensus Documents. J Am
Coll Cardiol 2010;55:2663–99.
24. Hausleiter J, Martinoff S, Hadamitzky
M, et al. Image quality and radiation
exposure with a low tube voltage pro-
tocol for coronary CT angiography:
results of the PROTECTION II
Trial. J Am Coll Cardiol Img 2010;3:
1113–23.
25. American College of Radiology. AC-
RIN seeking sites for cardiac imaging
trial. Available at: http://www.acr.org/
SecondaryMainMenuCategories/
NewsPublications/FeaturedCategories/
CurrentACRNews/ACRINAwarded
GrantAHRQ.aspx. Accessed October 29,
2010.
26. ClinicalTrials.gov. Prospective multi-
center imaging study for evaluation of
chest pain (PROMISE). Available at:
http://www.clinicaltrials.gov/ct2/
show/NCT01174550. Accessed Oc-
tober 29, 2010.
27. Otero HJ, Rybicki FJ, Greenberg D,
Mitsouras D, Mendoza JA, Neumann
PJ. Cost-effective diagnostic cardio-
vascular imaging: when does it provide
good value for the money? Int J Car-
diovasc Imaging 2010;26:605–12.
Key Words: comparative
effectiveness research y
computed tomography y
coronary imaging y outcome.
